Loading
Ann Partridge led the POSITIVE trial showing women can safely pause hormone therapy to have a baby.
Ann H. Partridge is Vice Chair of Medical Oncology and Director of the Program for Young Adults with Breast Cancer at Dana-Farber Brigham Cancer Center. She is known for leading the POSITIVE trial, which showed that women can safely pause endocrine therapy to have a baby, and for the Young Women's Breast Cancer Study. Her selected paper reports interrupting endocrine therapy to attempt pregnancy after breast cancer. She now directs Dana-Farber's adult survivorship and young women's breast cancer programmes, with a focus on fertility and life after cancer.
| Title | Journal | Year |
|---|---|---|
| Interrupting endocrine therapy to attempt pregnancy after breast cancer | New England Journal of Medicine | 2023 |
Shares Breast Cancer Research Foundation, HR-positive / HER2-negative breast cancer.
Shares Breast Cancer Research Foundation, HR-positive / HER2-negative breast cancer.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.
Shares Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer.